Journal ArticleDOI
American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
Joseph D. Feuerstein,Geoffrey C. Nguyen,Sonia S. Kupfer,Yngve Falck-Ytter,Siddharth Singh,Lauren B. Gerson,Ikuo Hirano,Joel H. Rubenstein,Walter E. Smalley,Neil Stollman,Shahnaz Sultan,Santhi Swaroop Vege,Sachin Wani,David H. Weinberg,Yu-Xiao Yang +14 more
Reads0
Chats0
TLDR
Therapeutic Drug Monitoring in Inflammatory Bowel Disease: Clinical Guidelines Committee concludes that the current literature on therapeutic drug monitoring is inadequate and calls for further research into this topic.About:
This article is published in Gastroenterology.The article was published on 2017-09-01. It has received 391 citations till now. The article focuses on the topics: Guideline & Inflammatory bowel disease.read more
Citations
More filters
Journal ArticleDOI
ACG Clinical Guideline: Management of Crohn’s Disease in Adults
Gary R. Lichtenstein,Edward V. Loftus,Kim L. Isaacs,Miguel Regueiro,Lauren B. Gerson,Bruce E. Sands +5 more
TL;DR: This guideline is intended to be flexible, not necessarily indicating the only acceptable approach, and should be distinguished from standards of care that are inflexible and rarely violated.
Journal ArticleDOI
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment
Joana Torres,Stefanos Bonovas,Glen A. Doherty,Torsten Kucharzik,Javier P. Gisbert,Tim Raine,Michel Adamina,Michel Adamina,Alessandro Armuzzi,Oliver Bachmann,Palle Bager,Livia Biancone,Bernd Bokemeyer,Peter Bossuyt,Johan Burisch,Paul Collins,Alaa El-Hussuna,Pierre Ellul,Cornelia Frei-Lanter,Federica Furfaro,Christian Gingert,Paolo Gionchetti,Fernando Gomollón,Marien González-Lorenzo,Hannah Gordon,Tibor Hlavaty,Pascal Juillerat,Konstantinos H. Katsanos,Uri Kopylov,Eduards Krustins,Theodore Lytras,Christian Maaser,Fernando Magro,John Marshall,Pär Myrelid,Gianluca Pellino,Isadora Rosa,João Sabino,Edoardo Savarino,Antonino Spinelli,Laurents P. S. Stassen,Mathieu Uzzan,Stephan R. Vavricka,Bram Verstockt,Janindra Warusavitarne,Oded Zmora,Gionata Fiorino +46 more
TL;DR: The present article addresses surgical management, including preoperative aspects and drug management before surgery, and provides technical advice for a variety of common clinical situations.
Journal ArticleDOI
AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis.
Joseph D. Feuerstein,Kim L. Isaacs,Yecheskel Schneider,Shazia M. Siddique,Yngve Falck-Ytter,Yngve Falck-Ytter,Siddharth Singh,Karen A. Chachu,Lukejohn W. Day,Benjamin Lebwohl,Thiruvengadam Muniraj,Amit Patel,Anne F. Peery,Raj J. Shah,Shahnaz Sultan,Harminder Singh,Stuart J. Spechler,Grace L. Su,Aaron P. Thrift,Jennifer M. Weiss,Adam V. Weizman,Joseph Feuerstein,Kim L. Isaacs,Jessica R. Allegretti,Jonathan P. Terdiman +24 more
TL;DR: In this article, the authors developed a guideline for the management of moderate-to-severe UC using the GRADE framework and in adherence to the standards established by the Institute of Medicine for the development of trustworthy guidelines.
Journal ArticleDOI
Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition.
Dan Turner,Frank M. Ruemmele,Esther Orlanski-Meyer,Anne M. Griffiths,Javier Martín de Carpi,Jiri Bronsky,Gábor Veres,Marina Aloi,Caterina Strisciuglio,Christian Braegger,Amit Assa,Claudio Romano,Seamus Hussey,Michael Stanton,Mikko P. Pakarinen,Lissy de Ridder,Konstantinos H. Katsanos,Nicholas M. Croft,Víctor Manuel Navas-López,David C. Wilson,Sally Lawrence,Richard K. Russell +21 more
TL;DR: These guidelines provide a guide to clinicians managing children with UC and IBD-unclassified management to provide modern management strategies while maintaining vigilance around appropriate outcomes and safety issues.
Journal ArticleDOI
Inflammatory Bowel Disease in Pregnancy Clinical Care Pathway: A Report From the American Gastroenterological Association IBD Parenthood Project Working Group.
Uma Mahadevan,Christopher J. Robinson,Nana Bernasko,Brigid S. Boland,Christina D. Chambers,Marla Dubinsky,Sonia Friedman,Sunanda V. Kane,Jacob Manthey,Jason Sauberan,Joanne Stone,Rajeev Jain +11 more
References
More filters
Book
Clinical Practice Guidelines We Can Trust
TL;DR: Clinical Practice Guidelines The authors Can Trust shows how clinical practice guidelines can enhance clinician and patient decision-making by translating complex scientific research findings into recommendations for clinical practice that are relevant to the individual patient encounter, instead of implementing a one size fits all approach to patient care.
Journal ArticleDOI
Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
Niels Vande Casteele,Marc Ferrante,Gert Van Assche,Vera Ballet,Griet Compernolle,Kristel Van Steen,Steven Simoens,Paul Rutgeerts,Ann Gils,Severine Vermeire +9 more
TL;DR: After dose optimization, continued concentration-based dosing of infliximab was not superior to clinically based dosing for achieving remission after 1 year, but was associated with fewer flares during the course of treatment.
Journal ArticleDOI
Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
Casper Steenholdt,Jørn Brynskov,Ole Østergaard Thomsen,Lars Kristian Munck,Jan Fallingborg,Lisbet Ambrosius Christensen,Gitte Pedersen,Jens Kjeldsen,Bent Ascanius Jacobsen,Anne Sophie Oxholm,Jakob Kjellberg,Klaus Bendtzen,Mark A. Ainsworth +12 more
TL;DR: Treatment of secondary IFX failure using an algorithm based on combined IFX and IFX antibody measurements significantly reduces average treatment costs per patient compared with routine IFX dose escalation and without any apparent negative effect on clinical efficacy.
Journal ArticleDOI
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar,Idan Levy,Yarden Yavne,Miri Yavzori,Orit Picard,Ella Fudim,Ronen Loebstein,Yehuda Chowers,Rami Eliakim,Uri Kopylov,Shomron Ben-Horin +10 more
TL;DR: It is proposed that serum levels of 6-10 μg/mL for infliximab and 8-12 μg/ mL for adalimumab are required to achieve mucosal healing in 80%-90% of patients with IBD, and that this could be considered as a "therapeutic window."
Journal ArticleDOI
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis
Omoniyi J. Adedokun,William J. Sandborn,Brian G. Feagan,Paul Rutgeerts,Zhenhua Xu,Colleen Marano,Jewel Johanns,Honghui Zhou,Hugh M. Davis,Freddy Cornillie,Walter Reinisch,Walter Reinisch +11 more
TL;DR: Serum concentrations of infliximab are associated with efficacy in patients with moderate-to-severe ulcerative colitis; however, complex factors determine the relationship between exposure to this drug and response.
Related Papers (5)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more